Daily Stock Analysis, FLKS, Flex Pharma Inc, priceseries

Flex Pharma Inc. Daily Stock Analysis
Stock Information
Open
128.88
Close
129.81
High
129.90
Low
128.88
Previous Close
128.88
Daily Price Gain
0.93
YTD High
138.91
YTD High Date
Jan 30, 2020
YTD Low
76.87
YTD Low Date
Jan 21, 2016
YTD Price Change
21.94
YTD Gain
20.34%
52 Week High
138.91
52 Week High Date
Jan 30, 2020
52 Week Low
76.87
52 Week Low Date
Jan 21, 2016
52 Week Price Change
21.94
52 Week Gain
20.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 5. 2016
93.48
Feb 9. 2017
109.97
36 Trading Days
17.64%
Link
LONG
Jul 10. 2017
105.21
Sep 20. 2017
117.66
40 Trading Days
11.83%
Link
LONG
Jul 2. 2018
107.84
Jul 30. 2018
114.65
16 Trading Days
6.32%
Link
LONG
Mar 19. 2019
115.37
Apr 25. 2019
124.74
21 Trading Days
8.12%
Link
LONG
Nov 27. 2019
126.32
Jan 6. 2020
134.12
20 Trading Days
6.17%
Link
Company Information
Stock Symbol
FLKS
Exchange
NasdaqGM
Company URL
http://www.flex-pharma.com
Company Phone
617-874-1821
CEO
Christoph H. Westphal
Headquarters
Massachusetts
Business Address
800 BOYLSTON STREET, 24TH FLOOR, BOSTON, MA 02199
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001615219
About

Flex Pharma, Inc. operates as a biotechnology company, which engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company was founded by Christoph Westphal and Jennifer M. Cermak on February 26, 2014 and is headquartered in Boston, MA.

Description

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development. Its lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis. The company also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. It markets and sells its HOTSHOT product online through its e-commerce Website, as well as through third-party Websites. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.